A Real-world Study to Assess Safety and Effectiveness of Secukinumab in Pediatric Plaque Psoriasis Patients in China

Inclusion Criteria

• •Patients meeting all of the following criteria are eligible for inclusion in this study:
• •Written assent and informed consent must be obtained as per local regulations prior to any study procedures.
• •Diagnosed with moderate to severe plaque psoriasis.
• •Initiating treatment with Cosentyx® or having started Cosentyx® treatment within the last 4 weeks in routine clinical practice, and its prescription is independent of this study.
• •Aged 6 to less than 18 years at the time they are prescribed Cosentyx®.
• •Have valid PASI and IGA mod 2011 score at the time they are prescribed Cosentyx®.